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Background: The use of bevacizumab in combination with fluoropyrimidine-containing chemotherapy is a well-
established first-line and second-line treatment for patients with metastatic colorectal cancer (mCRC). However,
there remains a need for reproducible, validated, inexpensive and accessible prognostic markers to aid treatment
selection. The optimal treatment duration and the role of bevacizumab in certain patient subgroups, considered at
particular risk of bevacizumab-mediated toxicity, also require further investigation. The aim of the ASCENT study [an
Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic
ColorEctal caNcer Treated with bevacizumab (Avastin™)] is to evaluate the relationship between the host
inflammatory response as measured by neutrophil/lymphocyte ratio (NLR) and treatment outcomes in patients with
previously untreated mCRC receiving bevacizumab-based first- and second-line treatment.
Methods/design: This open-label, prospective, single arm, phase IV, Australian multi-centre study evaluates the
relationship between the host inflammatory response as measured by NLR and treatment outcomes in patients
with previously untreated mCRC receiving bevacizumab-based first- and second-line treatment. 150 patients will be
recruited from 16 centres around Australia. Patients will receive trial treatments in two phases: Phase A: XELOX or
mFOLFOX6 plus bevacizumab administered from study start until first disease progression; and Phase B: FOLFIRI plus
bevacizumab administered from first disease progression until second disease progression. The primary analysis will
test the association between NLR and progression free survival using a proportional Hazards Model. Secondary
analyses will investigate whether the relationship can be improved upon with other prognostic biomarkers, and
further characterise the safety of bevacizumab following treatment initiation, and when continued after progression
in combination with standard chemotherapy regimens (presented through summary statistics and Kaplan Meier
curves).
Discussion: Quantifying the relationship between NLR and PFS will inform decision making on the extent to which
this simple metric may be applied clinically.
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Colorectal cancer (CRC) is the second most commonly
diagnosed cancer in Australia, with 14300 new cases and
4047 deaths (2,191 males; 1,856 females) [1] recorded in
2007. It is projected that 19000 new cases of CRC will be
diagnosed, in Australia, in 2020 [2]. Approximately 25% of
patients present with metastatic CRC (mCRC) at initial
diagnosis and another 25% will develop subsequent metas-
tases [3]. Treatment outcomes have improved significantly
in the last decade as a result of the introduction of new
systemic treatments and the expanded use of hepatic
metastatectomy; with median survivals now well in excess
of two years [4].
For the majority of patients diagnosed with mCRC
palliative chemotherapy is the most appropriate treat-
ment option in order to achieve the goals of prolonging
survival and improving quality of life (QoL). The back-
bone of first- and second-line palliative chemotherapy
for mCRC consists of a fluoropyrimidine (infusional
5-FU or oral capecitabine) based therapy in various
combinations and schedules. Combination chemotherapy
with fluoropyrimidine/oxaliplatin (FOLFOX or XELOX)
or 5-FU/LV/irinotecan (FOLFIRI) provides higher re-
sponse rates, longer progression-free survival (PFS) and
better overall survival (OS) than a fluoropyrimidine alone.
Both FOLFOX/XELOX and FOLFIRI have similar efficacy
regardless of the sequence used but have different toxicity
profiles [5]. Favorable survival has been shown to correlate
with the percentage of patients receiving all active chemo-
therapeutic agents, emphasizing the importance of expos-
ure to all active drugs during treatment [6].
The use of bevacizumab in combination with fluoro-
pyrimidine-containing chemotherapy is a well-established
first-line and second-line treatment for patients with mCRC
[7-13]. Despite this, a number of data gaps remain to be
addressed, notably, the need for reproducible, validated, in-
expensive and easy to administer prognostic biomarkers to
aid in treatment selection. The optimal treatment duration
and the role of bevacizumab in certain patient subgroups,
specifically those considered at particular risk of
bevacizumab-mediated toxicity, also require further
investigation.
An increasing proportion of patients with mCRC at first
presentation are treated with systemic chemobiologic
therapy without pre-emptive resection of the primary
tumour. Limited data currently exist to guide treatment
decisions in this setting and uncertainty exists around the
risk/benefit of bevacizumab-based treatment in patients
with a primary in situ tumour [14-16]. Although the re-
cent NSABP C-10 trial contributed important data regard-
ing bevacizumab use in the setting of an asymptomatic
colonic primary tumour [14], similar studies have not yet
been undertaken in patients with a minimally symptom-
atic primary colon cancer or those with an in situ primaryrectal cancer. It is therefore necessary to further study the
safety and effectiveness of bevacizumab in the setting of
an in situ primary rectal lesion.
A wealth of preclinical models support the notion that
vascular endothelial growth factor (VEGF) is continually
expressed throughout the lifecycle of the tumour and that
sensitivity to anti-VEGF therapy remains even after dis-
ease progression [17]. The continuation of bevacizumab
after disease progression on bevacizumab-based first-line
treatment (bevacizumab beyond progression or BBP) is
common practice in countries such as the United States
[18]. Multivariate analyses from two large observational
cohort studies (BRiTE and ARIES registries) [19,20] sug-
gest that BBP is an independent predictor of prolonged
survival in mCRC. Although the use of BBP has been
addressed in a recently published, randomized phase III
trial (ML18147) [21], this study was not open in Australia
and did not collect data on QoL.
Biomarkers play an increasingly important role in both
cancer research and clinical practice. They can be used
to assess prognosis and to predict how individual patients
will respond to specific treatments [22,23]. Despite con-
certed international research efforts, there has not yet
been a validated and easy to administer biomarker to
predict treatment outcomes for patients treated with
bevacizumab. A broad range of blood- and tumour
tissue-based markers have been explored during the de-
velopment phase of bevacizumab (preclinical > 10,000;
clinical > 100) with most of the existing data focused on
VEGF pathway markers, including tumour VEGF expres-
sion [24], or oncogene mutations such as K-Ras [25,26].
Relatively little attention has been paid to the role of bio-
markers associated with the tumour microenvironment
and host factors such as the inflammatory response. Both
the tumour microenvironment and the inflammatory re-
sponse are considered key aspects of cancer biology and
tumourigenesis [27] and are important regulators of
angiogenesis. Infiltration of small tumours by inflamma-
tory cells that produce proangiogenic ligands makes a con-
tribution to the angiogenic switch that drives tumour
growth. Tumour development and progression induced by
an inflammatory response is thought to be mediated by
pro-inflammatory cytokines stimulating pathways espe-
cially those mediated by the nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) and the
Signal transducer and activator of transcription 3 (STAT3)
[28]. Given the established link between systemic inflam-
mation and tumour angiogenesis the potentially valu-
able role of inflammatory markers as predictive or
prognostic tools in the setting of bevacizumab is of inter-
est. The use of blood-based inflammatory markers
such as neutrophil/lymphocyte ratio (NLR) as prognostic/
predictive biomarkers in patients receiving bevacizumab-
based chemotherapy has not yet been evaluated.
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diminished survival in patients with liver-only colorectal
metastases receiving neo-adjuvant chemotherapy prior
to hepatic metastectomy [29]. Patients in whom NLR
normalised after chemotherapy had significantly im-
proved 1-, 3- and 5-year survival which was similar to
patients with NLR ≤ 5 at baseline [29]. More recently, a
study by Chua et al. [30] demonstrated an elevated
NLR, pre-treatment, in patients with unresectable
mCRC, in approximately 30% of patients. In this patient
cohort, who underwent first-line combination chemo-
therapy, NLR was found to be an independent predictor
of clinical benefit, progression and survival. The NLR
was statistically significantly associated with overall sur-
vival (P < 0.0001). Patients with NLR ≤ 5 had median
overall survival of 19.1 months (95% CI 15.3–22.8) com-
pared with patients with NLR > 5 (11.3 months; 95% CI
8.3–14.3). In addition, normalization of the NLR after
one cycle of chemotherapy was associated with im-
proved progression free survival.
The primary objective of this study (NCT01588990;
ML25753) is to validate and quantify the prognostic value
of the host inflammatory response as assessed by the NLR
on Progression Free Survival. Secondary objectives include
firstly, investigating the relationship further in light of
other clinical and biological markers; secondly, providing
clinically relevant information regarding the safety, effect-
iveness and QoL outcomes prior to, and after, progression.
Patients will be treated with bevacizumab in combination
with standard chemotherapy regimens in a generalized,
community-based population of mCRC patients. The




Participating patients will provide written informed con-
sent. The study will be conducted in accordance with
local guidelines and in line with the principles of the
Declaration of Helsinki and Good Clinical Practice
Guidelines. Ethics approval has been obtained from all
participating institutions.
Study objectives
The primary objective of the study is to assess the prog-
nostic value of the host inflammatory response as assessed
by the NLR (≤ 5 versus > 5) on Progression Free Survival.
The secondary objectives are to further characterise the
safety profile of study treatment and evaluate its efficacy
following treatment initiation, initial response and when
continued after progression; to explore the role of NLR as
a predictor of OS in patients treated with bevacizumab; to
assess the association between post-baseline changes in
NLR and PFS and OS and NRL; to assess patient reportedQoL; and to assess the incidence of serious adverse events
related to the primary tumour in the primary in situ
patient cohort.
Exploratory objectives include further characterization
of the relationship between blood-based markers of sys-
temic inflammation [including liver-derived acute phase
proteins, NLR and platelet/lymphocyte (PLR) ratios and
the modified Glasgow Prognostic Score (mGPS)] and
standard biochemical parameters (including adjusted cal-
cium, bilirubin, alkaline phosphatase, aspartate transamin-
ase, alanine transaminase and γ-glutamyl transferase) and
therapeutic outcomes.
Study design
This is an open-label, prospective, single arm, phase IV,
Australian multi-centre study evaluating the relationship
between the host inflammatory response as measured by
NLR and treatment outcomes in patients with previously
untreated mCRC who will receive bevacizumab-based
first- and second-line treatment (trial design is illus-
trated in Figure 1). The trial consists of two phases of
treatment:
Phase A treatment: XELOX or mFOLFOX6 plus
bevacizumab administered from study start until first
disease progression;
Phase B treatment: FOLFIRI plus bevacizumab
administered from first disease progression until second
disease progression.
Bevacizumab infusions will be administered on a three-
weekly basis in combination with XELOX or on a two-
weekly basis in combination with mFOLFOX6 throughout
Phase A treatment until first disease progression or occur-
rence of unmanageable toxicity. Upon documented dis-
ease progression, Phase A treatment will be discontinued
and bevacizumab will be continued on a two-weekly basis
in combination with FOLFIRI (Phase B treatment) until
second disease progression or unmanageable toxicity.
Upon second disease progression, all study treatment will
be discontinued and patients will enter follow-up for
survival status and subsequent treatment for their mCRC.
Phase B treatment (bevacizumab plus FOLFIRI) will
commence within 4 weeks of the date of documented first
disease progression.
Investigational product
Bevacizumab administered beyond first disease progression
(Phase B) is considered to be the “investigational study
drug”. Bevacizumab administered as Phase A treatment is
considered to be standard-of-care “non-investigational
drug”. XELOX, mFOLFOX6 and FOLFIRI are considered
standard of care “non-investigational combination drug”.















Phase B treatment 2 
8 weekly 
assessments
Figure 1 Study design. Bev = bevacizumab. PD = progressive disease.
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and FOLFIRI, administered throughout study Phase A
and Phase B, are according to the local Australian treat-
ment recommendations and requirements. In Phase A
treatment, bevacizumab will be administered at a dose
of either 7.5 mg/kg iv to coincide with XELOX (where
bevacizumab will be administered every 3 weeks) or
5.0 mg/kg with mFOLFOX6 (where bevacizumab will be
administered every 2 weeks). The dose and regimens of
bevacizumab administered throughout Phase A are per
local recommendations and requirements. In Phase B
treatment, bevacizumab will be administered at a dose
of 5.0 mg/kg iv on day 1 every 2 weeks in combination
with FOLFIRI. The doses of bevacizumab in Phase B are
in line with the dose used in the Phase III study
(ML18147) and the observational studies, BRiTE and
ARIES [19-21]. The drug doses for each treatment phase
are summarized in Table 1.Table 1 Study treatment doses
Phase A
XELOX Oxaliplatin: 130 mg/m2 iv day 1
Every
3 weeks
Capecitabine: 1000 mg/m2 po twice daily days 1 to 14
Bevacizumab: 7.5 mg/kg iv day 1
mFOLFOX6 Oxaliplatin: 85 mg/m2 iv day 1
Every
2 weeks
Leucovorin*: 400 mg/m2 iv day 1
Fluorouracil: 400 mg/m2 iv day 1
Fluorouracil: 2400 mg/m2 continuous iv infusion over
46 hours day 1




* Investigators may elect to use low dose leucovorin i.e. either 20 mg/m2 or 50 mgPatient population and eligibility criteria
The target population for this study includes male
and female adult patients with histologically con-
firmed mCRC eligible to commence first-line treat-
ment with bevacizumab in combination with XELOX
or mFOLFOX6. Inclusion and exclusion criteria are
presented in Table 2.
Assessments and procedures
Patients who provide informed consent will be screened
7–14 days before the baseline visit. Patients who fulfill all
of the inclusion and none of the exclusion criteria will be
accepted into the study. Treatment will be commenced
within 7 days of the baseline visit. Patients will attend
study specific visits every 8 or 9 weeks (to coincide with
chemotherapy regimen) throughout Phases A and B. All
patients will undergo a safety assessment no later than 30 -
days after the last dose of study treatment in Phase A, andPhase B
Irinotecan: 180 mg/m2 iv day 1
Leucovorin*: 400 mg/m2 iv day 1
Fluorouracil: 400 mg/m2 iv day 1
Fluorouracil: 2400 mg/m2 continuous iv infusion over
46 hours day 1
Bevacizumab: 5.0 mg/kg iv day 1
total dose.
Table 2 Eligibility criteria
Inclusion criteria
Resected primary tumour population
1. Signed informed consent obtained prior to any
study specific procedures and willingness to comply
with study requirements (including biomarker
sampling and tumour sampling for biomarkers).
2. Patients must be ≥ 18 years old.
3. Histologically confirmed, previously untreated mCRC
and not a candidate for curative resection.
4. WHO performance status of 0–1.
5. Life expectancy of ≥ 3 months.
6. Eligible for XELOX, mFOLFOX6, FOLFIRI and
bevacizumab treatment in accordance with local
standards of care and guidelines.
Patients with primary tumour in situ
Resected primary tumour population inclusion criteria apply
in addition to the following criteria:
1. Intact primary tumour of the colon or rectum not
requiring surgical intervention prior to
commencing chemotherapy.
2. Minimally or asymptomatic primary tumour
(without obstruction, perforation or active
bleeding requiring transfusion).
Exclusion criteria
Resected primary tumour population
1. Previous chemotherapy for mCRC.
2. Previous neoadjuvant or adjuvant chemotherapy
completed within 6 months prior to commencement
of study treatment.
3. Radiotherapy within 28 days prior to enrolment or
from which patients have not yet recovered.
4. History of non-colorectal cancer (patients are eligible if
they have been disease-free for≥ 5 years and the risk
for recurrence is deemed low).
5. Presence of active inflammatory bowel disease.
6. History of gastrointestinal perforation.
7. Symptomatic or bulky peritoneal disease.
8. History of significant bleeding event(s).
9. Significant vascular disease.
10. Peripheral arterial thrombosis or other thrombotic
event within 6 months prior to commencement of
study treatment.
Patients with primary tumour in situ
Resected primary tumour population exclusion criteria apply
in addition to the following criteria:
1. Prior endoscopic management of the
current malignancy.
2. Acute diverticulitis.
3. Presence of intra-abdominal abscess.
4. Active gastroduodenal ulcer(s).
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30 days after the last dose of study treatment in Phase B.
Patients will have subsequent follow-up visits every
12 weeks until study end. At the study end, all patients will
have an end of study follow-up visit to evaluate progres-
sion, survival status and safety. And patients, who have
discontinued study treatment for reasons other than
progressive disease whilst in either Phase A or Phase B,
will enter follow-up.
All data for secondary outcomes will be collected on a
case record form (CRF) by the treating physician. Data
regarding QoL (EroQol-5-D, AQol-8D and FACT-C) will
be captured using self-reported questionnaires, at base-
line, during treatment period, and safety and survival
follow-up visits.
Statistical considerations and analytical plan
Sample size
Approximately 150 patients will be enrolled into the study
(approximately 105 resected primary tumour population
patients and approximately 45 primary in situ tumour
patients) or recruitment will cease after 24 months, which-
ever occurs first. The sample size was determined based
on the assumptions that the true incidence of NLR > 5
is 30%, the median PFS is 10.5 months in patients with
NLR ≤ 5, and all patients are followed for 24 months. The
incidence of NLR > 5 of 30% is based on the values
reported by Chua et al [30].
This provides approximately 80% power to detect a haz-
ard ratio of 1.7 for the effect of NLR on PFS in the primary
endpoint. It is anticipated that the hazard ratio for NLR in
the primary model will be larger than the hazard ratio
(1.6) observed in the multivariate analysis reported by
Chua et al. [30]. This is because the multivariate analysis
adjusted for the presence of hypoalbuminemia, which is
likely to be correlated with NLR, and would have reduced
the apparent association.
Analysis populations
The Full Analysis Set will include all patients who receive
at least one dose of bevacizumab. The “Primary In Situ
population” will include all patients in the Full Analysis
Set with a primary in situ tumour. The “Resected Primary
Tumour population” will include all patients in the Full
Analysis Set without a primary in situ tumour.
Statistical analysis
The primary analysis will be a Cox Proportional Hazards
model of baseline NLR (< 5 vs. ≥5) on Progression Free
Survival, adjusted for WHO performance status, presence
of metastatic disease in the liver, number of different sites
of metastatic disease, and presence of metastatic disease in
the liver with no other sites of involvement. Secondary
relationship analyses will build on this primary model by
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descriptive with no pre-defined hypotheses.
Recruitment and participating sites
Sixteen centres across Australia will participate in the
study.
Time-line for the study
The study has started recruitment in June 2012 and will
formally end 24 months after the date of the commence-
ment of treatment for the last patient enrolled or once all
patients have died or have withdrawn from the study,
whichever occurs first, but may be prematurely terminated
by the sponsor.
Discussion
To date there is no validated or reproducible prognostic
biomarker to assist clinicians with determining the most
likely treatment outcomes for patients with mCRC treated
with bevacizumab-containing regimens. Relatively little
attention has been paid to the role of host/tumour micro-
environment factors such as the inflammatory response
and whether anti VEGF therapy might be able to abrogate
an inflammatory microenvironment that is favourable to
tumour growth/metastasis. The influence of the host
inflammatory response, as measured by NLR, has not yet
been studied in the setting of bevacizumab and may repre-
sent a clinically useful prognostic marker. This study will
provide important data to clarify the role of NLR as a
prognostic factor in the setting of standard first-and
second-line therapy for mCRC. Due to the single arm
design of the study, NLR as a predictor of response to
bevacizumab cannot be established.
Secondary objectives of this study will further charac-
terise the safety and efficacy of bevacizumab beyond
progression in combination with standard chemotherapy
regimens in a more generalised, community-based popu-
lation of mCRC patients in Australia and will evaluate
treatment outcomes of approximately 45 patients pre-
senting with mCRC with a minimally symptomatic or
asymptomatic primary colon or rectal tumour.
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